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Abstract
Background: As obesity is becoming an epidemic, diet programs, including low-calorie 
diets, are continuously being developed. It is generally believed that a low-calorie 
diet is commonly followed by a resting metabolic rate decrease and ultimate weight 
regain. Ephedra sinica and evodia rutaecarpa are known to have sympathomimetic 
and anti-obesity effects.
Design and Objective: This study was a prospective; double-blinded, randomized 
and placebo-controlled clinical trial to evaluate the effects of ephedra sinica and 
evodia rutaecarpa on resting metabolic rate (RMR), body composition and short-
term safety in obese Korean premenopausal women on a low-calorie diet.
Methods: One hundred and twenty-five otherwise healthy obese women (body mass 
index ≥ 25 kg/m2) were recruited and randomly assigned to three groups: ephedra 
group (n = 41), evodia group (n = 45) and placebo group (n = 39). Subjects were admin-
istered ephedra extract in capsules (pseudo-ephedrine 31.52 mg) or evodia extract 
in capsules (evodiamine 6.75 mg, rutaecarpine 0.66 mg) or placebo capsules as well 
as participating in a low-calorie diet for 8 weeks. Resting metabolic rate and body 
composition were measured at baseline, 4 and 8 weeks. Basic serum tests were per-
formed to evaluate the short-term safety and lipid-lowering effects of the herbs.
Results: All three groups showed significant body mass index (BMI) decreases, proba-
bly due to the low-calorie diet. Among the groups, the most prominent BMI-reducing 
effect was seen in the ephedra group. In RMR, no significant change in any group or 
significant difference among the groups was found. No significant adverse effects 
were observed in serum tests or in the self-questionnaire.
Conclusion: Ephedra combined with a low-calorie diet was effective in reducing BMI. 
RMR change was not compensated for by the herbal medicines tried. RMR change 
seemed to be affected by constitution and body composition rather than by medicine. 
Ephedra and evodia were proven to be safe for short-term use in the herbal form.
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1. Introduction
The rising prevalence of obesity in the last 20−30 
years has led to obesity being characterized as an 
epidemic. The World Health Organization announced 
that obesity and its complications are the leading 
world-wide health threat [1]. Although numerous 
weight loss programs have been developed in con-
ventional medicine, their effectiveness has proven 
to be quite limited [2]. Meanwhile, alternative agents, 
including herbs used in Chinese medicine, have been 
consumed extensively in the United States and 
European countries for weight loss purposes. Among 
these agents, preparations that include ephedra 
are the most popular [3].
Ephedra is the stem of ephedra sinica, also known 
as ma-huang, and has been used in Chinese medi-
cine for over 5000 years as a treatment for the com-
mon cold, arthralgia, asthma and other ailments 
[4,5]. Because of its sympathomimetic effect, var-
ious herbal mixtures containing ephedra have been 
used for obesity treatment in western countries as 
well as in Asia.
The fruit of evodia rutaecarpa is regarded as a 
‘hot nature’ herb in Chinese literature. Evodiamine 
is a major component of the herb and manifests 
capsaicin-like vanilloid receptor agonist activity 
[6,7]. Some studies have reported that capsaicin 
and evodia have anti-obesity effects [6].
Energy expenditure is commonly divided into 
three components: resting metabolic rate (RMR), 
physical activity and thermogenesis induced by 
food intake, exposure to cold, and other stressors. 
RMR accounts for the largest proportion (60−75%) 
of total daily energy needs in individuals, but the 
contribution of a low RMR to the etiology of obesity 
is still controversial [1,8]. However, it is well estab-
lished that energy restriction and weight loss may 
cause a sustained suppression of the RMR for a given 
body composition [1]. The decreased RMR may be 
important for weight regain in obese subjects after 
weight loss during a diet program [9]. Therefore, 
clinicians involved in bariatric management have 
a great interest in keeping or enhancing the RMR 
of patients during a low-calorie diet.
In the present study, the authors hypothesized 
that the RMR decline, which may be a major factor 
for weight regain during a diet program, can be 
minimized by the metabolism promotion effect of 
ephedra and evodia, and that both herbs have 
some effects on body composition. The short-term 
safety of using ephedra and evodia was also eval-
uated by the means of blood chemistry and 
self-questionnaire.
2. Methods
2.1. Study design
The present study was a randomized, controlled, 
double-blind clinical trial to assess the efficacy 
and safety of herbal extracts of ephedra sinica and 
evodia rutaecarpa, and was conducted in Bundang 
CHA Hospital, South Korea for 8 weeks between 
December 2004 and May 2005.
A total of 142 women volunteered for the study 
by e-mail. Seventeen were not selected due to pos-
sible health hazards or incorrect body mass index 
(BMI; under 25 kg/m2). The remaining 125 volunteers 
had blood exams in the main laboratory of CHA 
Hospital on the first visit. The subjects, healthy 
Korean premenopausal women, were assigned to 
three groups of ephedra, evodia and placebo by ran-
domization. Randomization was conducted by choos-
ing a number from 1 to 125 already randomly allotted 
to three groups by randomization computer soft-
ware. 41, 45 and 39 subjects were thus allotted to 
the ephedra, evodia, placebo groups, respectively. 
The study was blinded for all researchers involved.
After assignment, subjects were educated on a 
healthy low-calorie diet of 1200 kcal/day. A diet 
diary was encouraged during the whole study pe-
riod to check dietary compliance. Moderate exer-
cise (40 minutes walk, five times in a week, 70% of 
maximum heart rate) was indicated. All other med-
icines, diet or exercise programs were prohibited 
during the study. After instruction, subjects were 
given a 4 week supply of herbal extract capsules 
in an opaque bottle. Unconsumed capsules were 
Table 1 Evaluation progress
 
1st visit
 2nd visit  3rd visit  4th visit
  Week 0 
Week 2
 Week 4 
Week 6
 Week 8
Body composition  ✓  ✓  ✓
Metabolic rate  ✓ Telephone ✓ Telephone ✓
WHR  ✓ counsel ✓ counsel ✓
Blood sampling ✓     ✓
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returned to the pharmacist after 4 and 8 weeks, 
and subjects who had not taken 2/3 of their cap-
sules were excluded from the study. On the second 
visit, resting metabolic rate, body composition and 
basic anthropometric parameters were measured. 
Between visits, a researcher contacted subjects by 
telephone to check on the diet program and remind 
them of the next scheduled visit. After 4 weeks 
and 8 weeks, the third and fourth visits were made 
to reexamine the resting metabolic rate, body com-
position and basic anthropometric parameters. A 
follow-up blood exam was only done at week 8 
(Table 1). Blood pressure was measured on the first 
and last visits. To evaluate adverse effects of both 
herbs, symptoms and signs were self-reported before 
and after the experiment.
Prior to the experiment, the basic purpose and 
principle of the study, potential adverse effects 
of herbal extracts as well as their right of with-
drawal from the study was thoroughly explained 
to all subjects, and subjects were asked to sign a 
personal consent form. The study was approved by 
the Institutional Review Board of Bundang CHA 
Hospital.
2.2. Subjects
Subjects were recruited by advertisements in local 
newspapers and on the webpage of Bundang CHA 
Hospital. To qualify, subjects needed to be pre-
menopausal Korean women between 21 and 50 
years of age and have a BMI over 25 kg/m2 and 
must have been weight-stable within ± 3 kg during 
the previous 6 months. Only non-smoking, moder-
ately sedentary housewives and office-workers who 
did not exercise regularly and walked less than 30 
minutes a day were recruited. Volunteers applied 
to the trial by e-mail and were screened by a re-
searcher. A physician interviewed the volunteers 
on their general health. Women with a past history 
of cardiovascular disease, renal or hepatic dys-
function, cancer, neurological or psychological ill-
ness or metabolic disease were excluded from the 
study. Any subject taking drugs that could affect 
metabolic rate was also excluded. Pregnancy at 
any time during the study was among the exclusion 
criteria.
During the study, subjects who did not keep to 
the recommended dietary program, moved to an-
other city or traveled abroad or who manifested ad-
verse effects of the drugs were dropped from the 
study. Also 26 subjects in the first 4 weeks and 16 
others in the last 4 weeks abandoned the program 
out of personal choice. In week 8, 57 subjects com-
pleted the study: 21 from the ephedra group, 20 
from the evodia group and 16 from the placebo 
group.
2.3. Preparation
Evodia and ephedra used in the study were obtained 
from the Department of Oriental Pharmacology at 
Bundang CHA Hospital (Bundang, Korea). After wash-
ing, each herb was hot water-extracted at 105°C 
for 70 minutes. The herbal solution was concentrated 
in a decompressed condition at 60°C. To obtain the 
powder extract, the solution was spray-dried. The 
herb powder was contained in 250 mg capsules. 
Subjects were ordered to take four capsules 30 min-
utes after each meal, three times a day, for a total 
of 12 capsules a day. The recommended maximum 
daily doses of ephedra and evodia in natural herb 
form are 12 g according to the Korean Oriental As-
sociation for the Study of Obesity. The effective 
acquisition rates of extraction in the study were 
17.4% and 24.9% in ephedra and evodia, respectively. 
Therefore, roughly 3 g of evodia (evodiamine 6.75 mg, 
rutaecarpine 0.66 mg) extract powder and 2 g of 
ephedra (pseudoephedrine 31.52 mg) extract powder 
were equivalent to 12 g of natural herbs. One gram 
of corn starch was added to the ephedra powder 
to make the amount identical to the evodia pow-
der. The placebo contained 3 g of corn starch in a 
capsule of identical appearance.
2.4.  HPLC analysis of standard materials to 
test samples
The Laboratory of Oriental Pharmacology, Oriental 
Medical Hospital, KyungHee University, Seoul, Korea, 
analyzed the samples of the herbal extracts by 
high-performance liquid chromatography (HPLC).
The hot water-extracted ephedra and evodia 
powder, each accurately weighed to 1 g, were put 
in a test tube and dissolved in 10 mL of 100% ethanol 
for the pseudoephedrine content of ephedra, in 10 mL 
of methanol (HPLC reagent, J.T. Baker Co. Ltd., NJ, 
USA) for the evodiamine content of evodia and 
10 mL of chloroform-acetonitrile mixed solution (1:1, 
v/v) for the rutaecarpine content of evodia. Filtering 
through a 0.45 μm syringe filter (PTFE, Waters, MA, 
USA) followed. Each marker substance (standard 
materials) used for the quantitative analysis was 
purchased: pseudoephedrine (Sigma-Aldrich, St. 
Louis, MO, USA), evodiamine (Wako Pure Chemicals 
India Ltd., Osaka, Japan), and rutaecarpine (Sigma-
Aldrich, St. Louis, MO, USA).
Each standard material was dissolved in the same 
reagent with the corresponding sample solution. 
The dissolved standard solution was diluted as 0.05, 
0.1, 0.25, 0.5 and 1.0 mg/mL, and the standard HPLC 
chromatogram obtained. The relationship between 
the concentration and the peak-area was mea-
sured by a minimum square method (R2 value) [10]. 
The HPLC apparatus was a Waters Breeze System 
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(717 + Autosampler, 2487 dual absorbance detector, 
1525 binary HPLC Pump, Waters Co., Milford, USA). 
Waters Empower System (Ver. 5.00) was used for 
data acquisition and integration. The quantities of 
standard materials contained in the sample pow-
der were calculated by the following formula: the 
amount (mg) of standard materials = [the quantita-
tive amount (mg) of standard materials *AT/AS]/n 
where n = 3, AT = the peak-area of test samples con-
taining standard materials and AS = the peak area 
of standard materials.
From the results of the standard calibration 
curve, R2 values of pseudoephedrine, evodiamine 
and rutaecarpine were 0.997, 0.997 and 0.998, 
respectively.
2.5. Evaluation
2.5.1. Resting metabolic rate
An indirect calorimeter (MedGem, Healthetech, 
USA) was used for the measurement of RMR. This 
hand-held device was comprised of a mask and the 
cylinder-shaped main unit with an LCD-indicator. 
The mask covered the nose and mouth and was 
connected to the main body. This calorimeter unit 
was auto-calibrated prior to each test. The subjects 
breathed normally through the mask for 12 minutes 
whilst sitting in a comfortable seat with their elbows 
propped against an armrest. To maximize the accu-
racy, all subjects were requested to fast for at least 
2 hours and to rest in a quiet place of room temper-
ature and humidity for at least 20 minutes. Because 
the menstrual period of subjects can affect the 
RMR, the examination date was scheduled during 
the follicular phase, which follows menstruation by 
approximately 2 weeks. Oxygen concentration in 
the inspired and expired airflow was measured by 
an authentic sensor. RMR is calculated from oxygen 
consumption and displayed on LCD in kcals/day at 
the conclusion of the test.
2.5.2.  Anthropometry and body 
composition
While they were wearing a hospital gown, partici-
pants’ body weight and height were measured to 
the nearest 0.1 kg and 0.5 cm respectively. The 
waist circumference and waist-to-hip ratio (WHR) 
were measured twice according to the WHO method 
by the same observer.
On the second visit, body composition was mea-
sured by the bioelectrical impedance analysis method 
(InBody 3.0, Biospace, Korea). This device measures 
the impedance through the eight tactile electrodes 
placed on palms, thumbs, heels, and soles. Each sub-
ject stood upright stepping onto the foot electrodes 
whilst loosely gripping the pipe-shaped hand elec-
trodes with arms held vertically. Lean body mass, 
body mass index and percent fat were measured and 
recorded. Follow-ups were made 4 and 8 weeks later.
2.5.3. Blood chemistry
Blood tests including fasting glucose, blood urea 
nitrogen (BUN), creatinine, high density lipoproteins 
(HDL)-cholesterol, triglyceride, total cholesterol, 
aspartate aminotransferase/alanine aminotrans-
ferase (AST/ALT), C-reactive protein, platelet count, 
red and white blood cell count, hemoglobin, hema-
tocrit and mean cell volume were carried out be-
fore the experiment and 8 weeks later to ensure 
the safety of the herbal medicines and examine the 
effect on the lipid profile. At the baseline, subjects 
with high fasting blood glucose (> 140 mg/dL) or 
possible liver problems (AST or ALT > 80 IU/L) were 
excluded. No other serious illnesses were found at 
the baseline blood test.
2.6. Data analysis
All results are expressed as mean ± SD. All analyses 
were conducted at the two-tailed 0.05 alpha level 
using SPSS 10.0 for Windows. General characteris-
tics among the groups were analyzed by means of 
analysis of variance (ANOVA) and chi-square test. 
A one-way repeated measures ANOVA (Scheffe’s post 
hoc) was used to compare the pattern of change of 
RMR, body composition parameters and blood pro-
files among the groups over 4 and 8 weeks. Linear 
regression analysis was performed to get equations 
and to evaluate the correlations between RMR 
change and other parameters.
3. Results
3.1. Study progress
125 subjects were randomized after 17 dropouts. 
During the first 4 weeks the ephedra, evodia, and 
placebo groups experienced 14, 19, and 16 subject, 
respectively. These were mostly due to transfer or 
personal choice (Figure 1). At the fourth week, 27, 
26 and 23 remained in each group, followed by an-
other six, six and seven dropouts respectively. At the 
last visit, 21, 20 and 16 subjects appeared and 
completed the study.
3.2. General characteristics of subjects
Among the three study groups, age, weight, RMR, 
WHR, fat free mass, fat percentage, serum choles-
terol and serum triglyceride were not different 
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statistically at the baseline (p > 0.05). Initial blood 
pressures between the ephedra and evodia groups 
were statistically different from each other (p < 0.05, 
Table 2).
3.3. Herbal analysis
The extracted ephedra powder contained 15.76 mg of 
pseudoephedrine in one gram of extracted ephedra 
Table 2 Subjects’ baseline assessment
 Ephedra group Evodia group Placebo group 
p*
 (n = 21) (n = 20) (n = 16)
Age (yr) 33.8 ± 7.9 34.8 ± 6.4 30.8 ± 7.4 N.S.
Body mass index (kg/m2) 27.4 ± 2.3 29.1 ± 2.9 27.9 ± 2.0 N.S.
Resting metabolic rate (kcal/d) 1481.7 ± 224.4 1593.5 ± 301.9 1563.8 ± 289.7 N.S.
Waist to hip ratio 0.91 ± 0.05 0.92 ± 0.07 0.90 ± 0.04 N.S.
Percent body fat (%) 36.0 ± 4.0 37.1 ± 3.5 36.1 ± 3.3 N.S.
Fat free mass (kg) 43.9 ± 3.6 46.7 ± 4.0 47.5 ± 5.0 0.016
Total cholesterol (mg/dL) 194.3 ± 25.7 174.9 ± 29.1 178.5 ± 22.3 0.039
Triglyceride (mg/dL) 138.3 ± 74.0 130.0 ± 76.4 121.3 ± 47.9 N.S.
Blood pressure, mmHg 114.0 ± 11.7/ 115.6 ± 10.9/ 122.0 ± 11.9/ 0.017
 (systolic/diastolic) 75.6 ± 7.7 79.4 ± 9.3 84.5 ± 12.3
*Analyzed by ANOVA for continuous variables and Chi-square test for categorical variables.
142 subjects evaluated
41 assigned to ephedra 45 assigned to evodia 39 assigned to placebo
27 remaining at wk 4 26 remaining at wk 4 23 remaining at wk 4
20 completed study
at wk 8
21 completed study
at wk 8
16 completed study
at wk 8
17 dropped;
2 BMI < 25 kg/m2
7 AST, ALT 80↑
5 Glucose 140↑
3 Glucose 140↑ + AST, ALT 80↑
16 dropped;
3 move out + travel
3 other disease
1 pregnancy
1 nausea
8 personal choice
19 dropped;
6 move out + travel
4 other disease
9 personal choice
14 dropped;
1 move out
4 other disease
9 personal choice
6 withdrew;
1 other disease
5 personal choice
7 withdrew;
1 move out + travel
1 other disease
5 personal choice
6 withdrew;
6 personal choice
125 randomized, BMI ≥ 25 kg/m2
healthy premenopausal women
Figure 1 Process and condition of each group. BMI = body mass index.
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powder, while in one gram of evodia extract, 2.25 mg 
of evodiamine and 0.22 mg of rutaecarpine were 
included (Table 3). Chromatograms of standard ma-
terials and a sample extract of pseudoephedrine 
(Figure 2), evodiamine (Figure 3), and rutaecarpine 
(Figure 4) are shown.
3.4. Body composition and RMR
The longitudinal changes of body composition pa-
rameters and RMR at weeks 0, 4, and 8 as well as 
cross-sectional comparison among groups are shown 
in the Table 4.
All three groups showed significant weight and 
BMI decreases. Among the groups, the ephedra group 
manifested the most prominent weight-reducing 
effect. The ephedra group showed a significant re-
duction of body weight compared with the evodia 
and the placebo groups in weeks 4 and 8. However, 
we could not find any significant RMR change. The 
waist-hip ratio was significantly changed in the 
ephedra (p < 0.01) and placebo groups (p < 0.05). 
Table 3 The quantitative analysis results of the ephedra and evodia by HPLC
Sample (+)-Pseudoephedrine Evodiamine Rutaecarpine
Ephedra sinica 15.76 ± 5.44 − −
Evodia rutaecarpa − 2.25 ± 0.46 0.22 ± 0.02
unit = mg/dried ex. g
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No significant difference of WHR between groups 
was observed at weeks 0, 4 and 8. The percent of 
body fat was significantly decreased in all three 
groups. However, no significant inter-group differ-
ence was found in percent body fat. While the fat 
free mass was preserved during 8 weeks in the evo-
dia and placebo groups, the ephedra group showed 
a significant decrease.
Multiple regression analysis of 57 subjects re-
gardless of groups was performed to investigate 
the relationship between RMR change and other 
variables (Table 5). The age, herbs administered and 
WHR showed no significant influence to the change 
of RMR. On the other hand, the percent of body fat 
and the fat free mass showed a positive correlation 
to the change of RMR, while BMI and baseline RMR 
proved to be correlated negatively.
3.5. Blood chemistry
The results of the serum test are shown in Table 6. 
At baseline, there was significant difference between 
Table 4 Changes of the body composition parameters
 Ephedra group Evodia group Placebo group 
p*
 (n = 21) (n = 20) (n = 16)
Resting metabolic rate (kcal/d)
 Baseline 1481.7 ± 224.4 1593.5 ± 301.9 1563.8 ± 289.7 N.S.
 After 4 wks  1483.8 ± 300.8 1568.5 ± 291.6 1597.5 ± 296.5 N.S.
 After 8 wks 1405.0 ± 265.4 1524.0 ± 289.6 1646.3 ± 359.5 N.S.
Body mass index (kg/m2)
 Baseline 27.4 ± 2.3 29.1 ± 2.9 27.9 ± 2.0 N.S.
 After 4 wks  26.4 ± 2.3‡ 28.4 ± 2.9‡ 27.3 ± 2.2‡ 0.035
 After 8 wks 25.7 ± 2.1‡ 28.0 ± 3.2‡ 27.3 ± 2.5† 0.020
Waist to hip ratio
 Baseline 0.91 ± 0.05 0.92 ± 0.07 0.90 ± 0.04 N.S.
 At wk 4  0.90 ± 0.05‡ 0.92 ± 0.05 0.89 ± 0.04† N.S.
 At wk 8 0.88 ± 0.05‡ 0.91 ± 0.05 0.89 ± 0.04† N.S.
Percent body fat (%)
 Baseline 36.0 ± 4.0 37.1 ± 3.5 36.1 ± 3.3 N.S.
 At wk 4 34.9 ± 4.1‡ 36.4 ± 3.9‡ 35.5 ± 3.4‡ N.S.
 At wk 8 33.7 ± 4.0‡ 36.0 ± 3.9‡ 35.2 ± 3.9† N.S.
Fat free mass (kg)
 Baseline 43.9 ± 3.6 46.7 ± 4.0 47.5 ± 5.0 0.030
 At wk 4  43.0 ± 3.6‡ 46.2 ± 4.3 47.1 ± 4.8 0.015
 At wk 8  42.5 ± 3.5‡ 45.8 ± 4.3 47.2 ± 5.1 N.S.
*Analyzed by one-way ANOVA between groups; †p < 0.05 and ‡p < 0.01 vs. baseline by paired t-test, respectively.
Table 5 Association between subject characteristics and RMR change by multiple regression analysis 
 Model 1 (adjusted R2 = 0.272) Model 2 (adjusted R2 = 0.272)
 B coefficient (Sig.) B coefficient (Sig.)
Age (yr) 0.6 (0.920)
Ephedra group Reference
Evodia group 65.9 (0.425)
Placebo group 108.1 (0.228)
Body mass index (kg/m2) −113.2 (0.007) −87.7 (0.002)
Baseline RMR (kcal/d)  −0.5 (0.001) −0.6 (< 0.001)
Waist to hip ratio 1451.6 (0.124)
Percent body fat (%) 47.5 (0.025) 49.1 (0.003)
Fat free mass (kg) 43.4 (0.006) 43.0 (0.001)
Model 1 included all of the assessed variables and Model 2 included only significant variables which remained after backward 
method. 
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groups only in BUN. In the variables for drug safety, 
decreases of AST in the ephedra group and BUN in 
the evodia and the ephedra groups were observed. 
Lipid profiles including total cholesterol and trig-
lyceride were significantly improved in the ephe-
dra group. All of the mean values are within the 
reference ranges.
3.6. Adverse effects
Subjects were required to fill out the self-
questionnaire about adverse events due to the 
herbs at 0, 4, and 8 weeks. In the ephedra group, 
when compared with the baseline, palpitation, in-
somnia, dry mouth and gastrointestinal symptoms 
such as anorexia, nausea, vomiting, and constipation 
were increased at week 8. Although incidence was 
lower in the ephedra group, the evodia group also 
showed increases of symptoms including palpita-
tion, trembling, dizziness, nervousness, gastrointes-
tinal symptoms etc. The placebo group complained 
of increased insomnia and eruption (Table 7).
4. Discussion
The main purpose of the present study was to 
prove that ephedra sinica and evodia rutaecarpa 
have anti-obesity effects in terms of the resting 
metabolic rate and body composition as well as 
showing that they are safe enough for short-term 
use during a low-calorie diet.
The resting metabolic rate (RMR) comprises 50−
80% of daily energy expenditure, and is highly variable 
between subjects. This variability is related to differ-
ences in fat free mass, fat mass, age and sex. RMR 
is believed to be genetically determined. Individuals 
with a low RMR are at higher risk of significant weight 
gain, relative to those with a high RMR [1,9].
The accurate assessment of RMR requires so-
phisticated methodologies. These include the use 
of human calorimeters, closed-circuit and open-
circuit indirect calorimetry equipment such as 
Douglas bags and gas analyzers and whole body 
respiratory chambers [8]. However, in the present 
study, a handheld indirect calorimeter was used. 
This device proved to be reliable when compared 
with the classic Douglas bag method [8].
Energy restriction and weight loss may cause a 
sustained suppression of the RMR for a given body 
composition. The suppression of RMR may be impor-
tant for understanding the high rate of weight re-
gain in obese subjects after weight loss. According 
to the analysis of Astrup [1], formerly obese sub-
jects had a 3−5% lower RMR than never-obese con-
trol subjects. In addition, a larger proportion of the 
formerly obese subjects had a low RMR (15.3% 
compared with 3.3%).
Table 6 Changes of the laboratory findings after treatment
 Ephedra group  Evodia group Placebo group 
p*
 (n = 21) (n = 20) (n = 16)
Aspartate transaminase (U/L)
 Baseline 17.7 ± 4.1 16.7 ± 3.8 18.0 ± 5.2 N.S.
 After 8 wks 15.5 ± 3.0† 20.0 ± 8.1 17.0 ± 4.5 N.S.
Alanine transaminase (U/L)
 Baseline 18.0 ± 8.7 19.0 ± 5.8 19.3 ± 10.2 N.S.
 After 8 wks 15.5 ± 7.9 24.3 ± 14.9 15.7 ± 6.6 0.016
Blood urea nitrogen (mg/dL)
 Baseline 13.2 ± 3.4 11.7 ± 3.5 10.6 ± 2.8 0.041
 After 8 wks 11.8 ± 2.8 10.6 ± 2.8† 11.1 ± 2.3 N.S.
Creatinine (mg/dL)
 Baseline 0.78 ± 0.08 0.78 ± 0.12 0.75 ± 0.08 N.S.
 After 8 wks 0.80 ± 0.09 0.78 ± 0.14 0.77 ± 0.10 N.S.
Total cholesterol (mg/dL)
 Baseline 194.3 ± 25.7 174.9 ± 29.1 180.4 ± 21.7 0.039
 After 8 wks 170.1 ± 23.9‡ 176.4 ± 34.2 173.7 ± 28.7 N.S.
Triglyceride (mg/dL)
 Baseline 138.3 ± 74.1 130.0 ± 76.4 122.9 ± 49.2 N.S.
 After 8 wks 100.3 ± 56.3† 111.4 ± 43.4 114.8 ± 55.0 N.S.
*Significance was calculated by one-way ANOVA, and Scheffe’s post hoc test revealed p < 0.05 in the difference between the 
maximum value and the minimum value; †p < 0.05 and ‡p < 0.01 vs. baseline by paired t-test, respectively. 
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In order to minimize the RMR decrease during 
calorie-restricted diet, numerous medical methods 
have been designed. Exercise added to a diet pro-
gram seems to maintain lean body mass, a condition 
which may prevent a decline in RMR [11]. In addi-
tion, sympathomimetic agents are prescribed to 
compensate for RMR decrease. On the other hand, 
herbal anti-obese products are obtaining increasing 
worldwide popularity because of their easy acces-
sibility and apparent safety. Among several commer-
cialized herbs with sympathetic stimulating effects, 
ephedra is one of the most popular [3].
Ephedra sinica contains 1−2% alkaloids com-
posed of ephedrine and pseudoephedrine. The main 
component ephedrine has been called an “ener-
gizer” for stimulating the central nervous system 
and the heart, increasing the heart rate and often 
elevating blood pressure. Although its anti-obesity 
effect through fat-burning and appetite-suppression 
is not fully approved, it is a common ingredient in 
many weight loss and energy-enhancing products 
[12,13].
Several studies have already combined a low-
calorie diet with ephedra or ephedrine. Malchow-
Moller et al reported that a low-calorie diet with 
ephedrine (180 mg/day) and caffeine (600 mg/day) 
group showed a significant weight loss of 4.0 kg 
compared with a placebo group [14]. Boozer et al 
also demonstrated an herbal supplement contain-
ing ma-huang (72 mg/day ephedrine) and guarana 
was significantly effective in weight reduction in 
an 8-week controlled trial [3].
In the present study, although the evodia and 
placebo groups also showed a significant weight-
reducing effect at weeks 4 and 8, ephedra was the 
most effective herb. The WHR reduction was also 
most obvious in the ephedra group, although no 
significant difference among groups was observed. 
In Astrup’s study [15] with ephedrine and caffeine, 
a significant body composition benefit was found; 
more fat loss, less fat-free mass loss. In the present 
study, although we also observed a distinct percent 
body fat decrease—meaning relatively greater fat 
mass reduction than fat free mass—in the ephedra 
group, no statistical significance among groups was 
found.
Several sympathomimetic agents has been tried 
to elucidate their pharmacological mechanism in 
terms of metabolic rate. Sibutramine [16], phenyl-
propanolamine [17] and phentermine [18] were 
tried to assess RMR-promoting and weight-reducing 
effects. Despite significant weight loss and ano-
rexic effects, they failed to demonstrate the drugs’ 
mechanism as RMR-promoters. In a clinical trial with 
ephedra, Vukovich demonstrated an acute dose of 
the herb combined with caffeine increased resting 
energy expenditure (REE) by 8.5% compared with 
the placebo trial [19]. However, the author em-
phasized that although significant, the increase in 
energy expenditure is negligible in terms of weight 
loss. Another study of Greenway also showed 8% 
of RMR increase in an ephedra with caffeine group 
when measured after 2 hours of administration. 
Beyond the acute effect, there is Astrup’s study 
[15]. The ephedra with caffeine group showed sig-
nificantly less decrease of 24-hour energy expendi-
ture compared with placebo after 8 weeks of an 
energy restricted diet.
In the present study, however, the authors failed 
to prove that ephedra has any chronic RMR-promoting 
effect during the 8-week low-calorie diet. An acute 
RMR-promoting effect was not evaluated in the 
Table 7 Adverse effects in the three groups for 8 weeks
 Ephedra (n = 21) Evodia (n = 20) Placebo (n = 16)
 Wk 0 Wk 4 Wk 8 Wk 0 Wk 4 Wk 8 Wk 0 Wk 4 Wk 8
Palpitation 0 1 1 0 1  1 0 0 0
Headache 7 5 7 3 1 2 2 1 0
Dull head 8 3 4 2 1 2 3 0 0
Tremble 0 1 0 0 0 1 1 1 0
Insomnia 0 3 4 2 2 2 1 0 2
Dizziness 4 5 4 2 1 3 4 1 0
Nervousness 2 0 1 0 0 1 2 1 1
Nausea 0 2 2 0 0 0 0 1 0
Vomiting 0 3 2 0 1 1 0 0 0
Anorexia 0 3 1 0 1 1 0 0 0
Constipation 8 11 12 3 1 4 4 6 3
Dysuria 0 0 0 0 0 1 1 1 0
Eruption 0 0 0 0 0 0 0 0 1
Dry mouth 0 5 6 0 1 1 1 1 1
Breathlessness 0 1 0 0 0 0 0 0 0
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present study. We suppose the weight reduction does 
not seem to be affected by RMR promotion.
To elucidate which parameter most affected 
the change of RMR, multiple regression analysis was 
performed. The result showed that body composi-
tion most influenced the change of RMR. In partic-
ular, higher lean body mass and percent body fat 
can predict more change in RMR while a higher BMI 
and baseline RMR can be interpreted as factors 
for a more stable RMR. On the other hand, no herb 
affected RMR change significantly. This analysis 
signifies that body composition, closely associated 
with genetic factor, as asserted in Astrup’s study 
[1], is more important to predict RMR change during 
an energy-restricted diet.
Evodia has been prescribed for the treatment of 
headache, thoracicoabdominal pain and vomiting 
that are caused by ‘cold’, or ‘cold constitution’ in 
Oriental medicine because of its ‘hot nature’. Several 
animal studies about evodia were focused on the 
cardiotonic, broncho-constrictive effect possibly 
associated with the vanilloid receptors of evodi-
amine [7,20]. Although via the capsaicin-like sym-
pathetic stimulation of evodiamine, an anti-obesity 
effect of herbal evodia could be reasonably antici-
pated, evidence is not sufficient at the present time. 
Only Kobayashi reported that evodiamine prevented 
perivisceral fat accumulation and body weight in-
crease through the enhancement of lipolysis [6]. In 
the present study, evodia, contrary to the author’s 
belief, failed to prove a weight-reducing effect 
or an RMR-promoting effect. Despite the fact that 
the weight was decreased in weeks 4 and 8 when 
compared with the baseline in the evodia group, 
there was no significant difference from the placebo 
group.
The safety of herbal ephedra is still extremely 
controversial. When compared with other herbal 
products such as ginkgo biloba and ginseng, using 
ephedra proved to be more risky in Bent’s study 
[12]. A number of anecdotal adverse events possi-
bly due to ephedra supplements led the FDA to ban 
the sale of dietary supplements containing ephedra 
[21] while regulation is more relaxed by far in the 
EU [4]. Several clinical studies support the safety 
of ephedra [22−24]. Greenway reported ephedra 
was safe both in the herbal and pharmaceutical 
forms mixed with caffeine [22].
In the present study, no renal or hepatic adverse 
effect was found in the serum test after 8 weeks 
of experimenting with either herb. Instead, trig-
lyceride and total cholesterol were significantly 
decreased in the ephedra group after 8 weeks, which 
is probably due to significant weight reduction.
The result of adverse events in the present study 
was also not different from those of previous stud-
ies. Compared with the placebo group, the ephedra 
group expressed several increased complaints such 
as dry mouth, nausea and vomiting, insomnia and 
anorexia, which are stereotypes of sympathomimetic 
effects of ephedra. However, none of the adverse 
events were severe to the extent of cessation of 
the experiment, except in one case of nausea in the 
placebo group. However headaches and dull head 
symptoms were improved after the 8-week diet, 
seemingly due in part to weight loss. In the evodia 
group, although several adverse events happened, 
none of them seem to have been significant. Because 
the number of cases of adverse events were insuf-
ficient, statistical analysis was not performed.
Our study had several limitations. More than half 
the volunteers dropped out unexpectedly. Many of 
them abandoned the experiment due to a failure 
to maintain the low-calorie diet. More frequent 
visits to the clinic or telephone counseling may be 
the answer in the future. A more variable dose 
of herbs should be tried. We needed to evaluate 
dose-dependent effects of both herbs. Furthermore, 
statistically we didn’t use an Intention-to-Treat 
method, which was standard for efficacy measure-
ment. However, as the major outcomes from this 
study are mainly negative, we consider the altera-
tion of statistical analysis would not change the 
principal results.
We conclude that both herbs’ effects on the al-
teration of RMR were less significant than expected 
although ephedra with a low-calorie diet was ef-
fective in reducing weight. RMR decrease in a low-
calorie diet seems to be self-limiting when the diet 
is lengthened. RMR change seems to be affected by 
constitution and body composition rather than by 
medicine. Ephedra and evodia were proved to 
be safe for short-term use in herbal form.
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